Hospital
Aspirus Wausau Hospital, INC
Aspirus Wausau Hospital, INC was paid $16.31M by Medicaid between Jan 2018 and Dec 2024, across 353 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 11% of everything it billed.
33Billing provider infoASPIRUS WAUSAU HOSPITAL, INC
WAUSAU, WI 54401
WAUSAU, WI 54401
33aNPI1558363986assigned 08/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.31M
24GClaims966,729
24DCodes billed353
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#11 of 60
Median peer was paid$2.90M
This provider vs. median5.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 138,681 | $2.20M | |
| 2019 | 131,017 | $2.25M | |
| 2020 | 124,662 | $2.03M | |
| 2021 | 132,382 | $1.90M | |
| 2022 | 149,473 | $2.61M | |
| 2023 | 160,889 | $2.79M | |
| 2024incomplete | 129,625 | $2.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 17,797 | 13,445 | $1.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.2% | 19,865 | 17,204 | $1.02M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 16,307 | 14,326 | $992K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 22,297 | 19,105 | $981K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.2% | 8,607 | 7,615 | $845K |
| 80053 | Comprehensive metabolic panel | 4.8% | 47,545 | 37,579 | $783K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 11,816 | 10,442 | $734K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.4% | 1,330 | 1,167 | $397K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.4% | 5,338 | 4,254 | $385K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 5,818 | 5,228 | $313K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 5,978 | 3,812 | $313K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 5,954 | 5,316 | $287K |
341 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 7,158 | $279K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.7% | 6,464 | $270K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 47,909 | $247K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 4,250 | $235K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 9,962 | $235K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 27,084 | $231K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.3% | 2,438 | $216K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,566 | $190K |
| 87070 | 1.1% | 9,494 | $184K | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 3,990 | $181K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 3,110 | $164K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,173 | $162K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,148 | $157K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,219 | $155K |
| 76801 | <1% | 2,239 | $140K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,160 | $134K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,068 | $125K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,162 | $124K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,772 | $114K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,101 | $108K |
| 81025 | <1% | 4,025 | $106K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,404 | $106K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,959 | $103K |
| 93296 | <1% | 4,896 | $97K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,152 | $95K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,686 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,871 | $92K |
| 81001 | <1% | 24,305 | $83K | |
| 86850 | <1% | 4,509 | $81K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,826 | $80K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,276 | $77K |
| 97597 | <1% | 1,950 | $75K | |
| 80306 | <1% | 5,380 | $67K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,555 | $60K |
| 96367 | <1% | 1,255 | $60K | |
| 83690 | <1% | 14,627 | $59K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,416 | $58K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,813 | $57K |
| 84484 | <1% | 9,085 | $56K | |
| 84703 | <1% | 7,989 | $55K | |
| 85027 | <1% | 11,096 | $54K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,470 | $54K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,627 | $53K |
| 80061 | Lipid panel | <1% | 4,082 | $52K |
| 83880 | <1% | 3,286 | $52K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,804 | $51K |
| 82962 | <1% | 5,275 | $51K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,792 | $48K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,316 | $48K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,592 | $48K |
| 85610 | <1% | 8,411 | $47K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,180 | $46K |
| 84702 | <1% | 2,421 | $46K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,336 | $45K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,779 | $44K |
| 82948 | <1% | 8,734 | $42K | |
| 82565 | <1% | 3,230 | $41K | |
| 29581 | <1% | 718 | $41K | |
| G0378 | Hospital observation service, per hour | <1% | 2,465 | $39K |
| 83735 | <1% | 10,200 | $37K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,956 | $33K |
| 93458 | <1% | 88 | $32K | |
| 83605 | <1% | 6,488 | $31K | |
| 87077 | <1% | 4,439 | $31K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 484 | $27K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,425 | $26K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 746 | $26K |
| 84439 | <1% | 1,883 | $26K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 156 | $25K |
| 70496 | <1% | 389 | $25K | |
| 93976 | <1% | 795 | $24K | |
| 72100 | <1% | 1,690 | $24K | |
| 87631 | <1% | 215 | $23K | |
| 93971 | <1% | 750 | $23K | |
| 74018 | <1% | 1,928 | $22K | |
| 70498 | <1% | 349 | $21K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 414 | $21K |
| 76642 | <1% | 609 | $21K | |
| 87040 | <1% | 3,648 | $19K | |
| 87088 | <1% | 3,597 | $19K | |
| 82977 | <1% | 3,601 | $18K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,000 | $18K |
| 82550 | <1% | 5,808 | $17K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 416 | $17K |
| 76536 | <1% | 297 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 360 | $16K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,911 | $16K |
| 87186 | <1% | 3,843 | $16K | |
| 82728 | <1% | 1,190 | $16K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,214 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,403 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,383 | $15K |
| 84132 | <1% | 2,435 | $15K | |
| 87505 | <1% | 120 | $14K | |
| 85379 | <1% | 2,316 | $14K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 48 | $13K |
| 82607 | <1% | 1,033 | $13K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 98 | $13K |
| 94060 | <1% | 620 | $13K | |
| 71250 | <1% | 450 | $12K | |
| 87210 | <1% | 998 | $12K | |
| 12001 | <1% | 131 | $12K | |
| 87807 | <1% | 266 | $11K | |
| 64493 | <1% | 49 | $11K | |
| 90715 | <1% | 1,079 | $11K | |
| 86140 | <1% | 2,726 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 910 | $11K |
| 73630 | <1% | 1,458 | $10K | |
| 86900 | <1% | 4,515 | $10K | |
| 93271 | <1% | 801 | $10K | |
| 96415 | <1% | 162 | $10K | |
| 73610 | <1% | 1,192 | $10K | |
| 76770 | <1% | 135 | $9K | |
| 86618 | <1% | 578 | $9K | |
| 72040 | <1% | 355 | $9K | |
| 87653 | <1% | 208 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 437 | $8K |
| 82010 | <1% | 1,611 | $8K | |
| 86901 | <1% | 4,515 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 385 | $7K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 264 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,918 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,541 | $7K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 177 | $7K |
| 87075 | <1% | 1,724 | $7K | |
| 85007 | <1% | 2,634 | $6K | |
| 96417 | <1% | 145 | $6K | |
| 94726 | <1% | 650 | $6K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 81 | $6K |
| 86803 | <1% | 522 | $6K | |
| 82043 | <1% | 809 | $6K | |
| 83550 | <1% | 1,167 | $6K | |
| 87081 | <1% | 130 | $6K | |
| 87205 | <1% | 2,805 | $5K | |
| S5161 | Emergency response system; service fee, per month (excludes installation and testing) | <1% | 172 | $5K |
| 80081 | <1% | 97 | $5K | |
| 82746 | <1% | 604 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,095 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,821 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 200 | $5K |
| 73030 | <1% | 1,080 | $5K | |
| 93298 | <1% | 342 | $5K | |
| 83540 | <1% | 1,275 | $5K | |
| 73564 | <1% | 1,263 | $4K | |
| 85652 | <1% | 2,221 | $4K | |
| 72141 | <1% | 64 | $4K | |
| 77336 | <1% | 142 | $4K | |
| 94729 | <1% | 661 | $4K | |
| 86480 | <1% | 78 | $3K | |
| 82553 | <1% | 973 | $3K | |
| 85049 | <1% | 338 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,368 | $3K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,155 | $3K |
| 12011 | <1% | 60 | $3K | |
| 73110 | <1% | 336 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 78 | $3K |
| 85730 | <1% | 595 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 598 | $3K |
| 74019 | <1% | 446 | $3K | |
| 81514 | <1% | 14 | $3K | |
| 74174 | <1% | 61 | $3K | |
| 84481 | <1% | 184 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,447 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 523 | $2K |
| 73130 | <1% | 685 | $2K | |
| 82950 | <1% | 252 | $2K | |
| 82805 | <1% | 114 | $2K | |
| 85018 | <1% | 619 | $2K | |
| 84512 | <1% | 390 | $2K | |
| 84153 | <1% | 148 | $2K | |
| 73502 | <1% | 545 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 42 | $2K |
| 64483 | <1% | 13 | $2K | |
| 87468 | <1% | 103 | $2K | |
| 87484 | <1% | 103 | $2K | |
| 87469 | <1% | 103 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,806 | $2K |
| 82657 | <1% | 136 | $2K | |
| 87340 | <1% | 183 | $2K | |
| 84403 | <1% | 57 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 195 | $2K |
| 91322 | <1% | 35 | $1K | |
| 90677 | <1% | 152 | $1K | |
| 87510 | <1% | 89 | $1K | |
| 87480 | <1% | 89 | $1K | |
| 87660 | <1% | 89 | $1K | |
| 80050 | General health panel | <1% | 539 | $1K |
| 97162 | <1% | 229 | $1K | |
| 80074 | <1% | 30 | $1K | |
| 90686 | <1% | 457 | $1K | |
| 72197 | <1% | 12 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 366 | $1K |
| 72110 | <1% | 53 | $1K | |
| 82570 | <1% | 267 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 323 | $1K |
| 84145 | <1% | 101 | $1K | |
| 82784 | <1% | 135 | $1K | |
| 90662 | <1% | 183 | $1K | |
| 88307 | <1% | 74 | $1K | |
| 86592 | <1% | 282 | $1K | |
| 97161 | <1% | 174 | $1K | |
| 71271 | <1% | 25 | $984.79 | |
| 86762 | <1% | 77 | $959.42 | |
| 94150 | <1% | 115 | $948.01 | |
| 87328 | <1% | 65 | $902.67 | |
| 84100 | <1% | 408 | $868.94 | |
| 90656 | <1% | 128 | $850.70 | |
| 84112 | <1% | 13 | $821.47 | |
| 70491 | <1% | 13 | $818.19 | |
| 86039 | <1% | 65 | $809.04 | |
| 96368 | <1% | 17 | $793.28 | |
| 12002 | <1% | 14 | $754.96 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,152 | $727.81 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $707.68 |
| 84460 | <1% | 166 | $675.32 | |
| 99152 | <1% | 1,834 | $645.06 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,796 | $640.39 |
| 93798 | <1% | 52 | $640.29 | |
| 87329 | <1% | 53 | $636.48 | |
| 94770 | <1% | 19 | $632.76 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,406 | $618.62 |
| 83970 | <1% | 21 | $569.86 | |
| 84156 | <1% | 222 | $568.49 | |
| 90480 | <1% | 38 | $550.33 | |
| 90651 | <1% | 12 | $520.68 | |
| 85014 | <1% | 252 | $515.55 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 84 | $495.00 |
| 70486 | <1% | 29 | $491.01 | |
| 82150 | <1% | 13 | $463.79 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 175 | $452.37 |
| 82378 | <1% | 88 | $450.62 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 3,309 | $440.16 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,416 | $439.19 |
| 83655 | <1% | 26 | $428.22 | |
| 36591 | <1% | 791 | $423.52 | |
| 80076 | <1% | 18 | $371.35 | |
| 95012 | <1% | 14 | $366.08 | |
| C1729 | Catheter, drainage | <1% | 573 | $354.44 |
| J2704 | Injection, propofol, 10 mg | <1% | 15,211 | $352.81 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,296 | $332.76 |
| 78320 | <1% | 15 | $330.69 | |
| 99205 | Prolong outpt/office vis | <1% | 28 | $329.39 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 18 | $326.45 |
| 84436 | <1% | 43 | $326.38 | |
| 86308 | <1% | 12 | $320.27 | |
| 87046 | <1% | 106 | $310.14 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,123 | $308.37 |
| G0008 | Administration of influenza virus vaccine | <1% | 853 | $299.68 |
| 82533 | <1% | 14 | $288.47 | |
| J1815 | Injection, insulin, per 5 units | <1% | 618 | $270.25 |
| 93299 | <1% | 13 | $258.84 | |
| 76000 | <1% | 81 | $256.84 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,533 | $238.40 |
| 73140 | <1% | 15 | $233.48 | |
| 96376 | <1% | 4,218 | $221.41 | |
| J3490 | Unclassified drugs | <1% | 736 | $196.55 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,259 | $190.22 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,616 | $188.94 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,225 | $185.36 |
| 93242 | <1% | 13 | $182.24 | |
| 94010 | <1% | 12 | $172.54 | |
| 94762 | <1% | 23 | $158.18 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,194 | $151.41 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,137 | $139.87 |
| 84450 | <1% | 48 | $135.59 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 25 | $122.85 |
| 73080 | <1% | 38 | $119.00 | |
| 82947 | <1% | 14 | $101.64 | |
| 86431 | <1% | 16 | $100.36 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,744 | $94.15 |
| 82272 | <1% | 64 | $82.50 | |
| 36000 | <1% | 2,241 | $81.38 | |
| 97165 | <1% | 42 | $76.62 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,630 | $71.64 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 264 | $70.70 |
| 89055 | <1% | 12 | $69.72 | |
| C1769 | Guide wire | <1% | 2,880 | $53.06 |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,009 | $51.64 |
| 87147 | <1% | 15 | $49.16 | |
| 81003 | <1% | 39 | $41.76 | |
| 97116 | <1% | 56 | $39.46 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 863 | $39.17 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,016 | $38.02 |
| 85347 | <1% | 20 | $35.36 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 342 | $34.59 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 832 | $30.58 |
| 97166 | <1% | 18 | $28.65 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,770 | $24.42 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 89 | $23.48 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,484 | $22.34 |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 448 | $18.44 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,962 | $17.12 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,563 | $16.62 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 383 | $15.97 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 1,525 | $13.85 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,189 | $12.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 425 | $9.75 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,238 | $8.31 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,477 | $8.14 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 403 | $7.51 |
| 36592 | <1% | 87 | $7.49 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 13 | $5.38 |
| 88112 | <1% | 19 | $4.11 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 725 | $3.55 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 39 | $3.36 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,517 | $3.08 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 972 | $2.88 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,135 | $2.22 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 555 | $2.02 |
| 88342 | <1% | 190 | $1.53 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 718 | $1.42 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 207 | $0.54 |
| A9270 | Non-covered item or service | <1% | 11,555 | $0.29 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 109 | $0.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 119 | $0.01 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 163 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 767 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 672 | $0.00 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 199 | $0.00 |
| 88304 | 0% | 71 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 36 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 45 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 68 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 389 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 375 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,085 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 201 | $0.00 |
| 36600 | 0% | 41 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 173 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 122 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 17 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 14 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 27 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 16 | $0.00 |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 14 | $0.00 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 12 | $0.00 |
| 73590 | 0% | 13 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.